
Mayo Clinic researchers identify a measurable genetic mutation as a significant predictor of metastasis and survival in pancreatic cancer
PDAC is an aggressive form of cancer that is often difficult to diagnose. Most patients already have cancer spread to other parts of their body when initially diagnosed, and current tests often miss this hidden spread. This makes it challenging to determine the best treatment strategy. The findings, published in the Annals of Surgical Oncology, may help identify patients who are more likely to have cancer spread to other parts of the body, therefore providing doctors and patients with the right information to make informed decisions about treatment.
'This is a major advancement for pancreatic ductal adenocarcinoma,' says Mark Truty, M.D., hepatobiliary and pancreatic surgical oncologist within Mayo Clinic's Department of Surgery. Dr. Truty is senior author of the study. 'We've had this genetic testing available for a number of years, however, we did not know the significance of the results or how to interpret them. Having the KRAS status will allow the patient and their provider to make better decisions about their individual cancer treatment.'
The prospective cohort study, involving nearly 800 patients — the largest patient series to date in the literature using ctDNA — found that 20%-30% of patients with PDAC have detectable mutant KRAS ctDNA in the blood and/or peritoneum, and that those without any previous treatment, such as chemotherapy, had the highest incidence. Thus, the study suggests that ctDNA assays should be performed prior to treatment to have the highest yield.
The researchers examined data between 2018 and 2022. Blood sample tests revealed that 104 patients (14%) had KRAS ctDNA mutation. These patients were more likely to develop advanced, spreading cancer and had a lower survival rate. Further testing of fluid from around the abdominal cavity in 419 patients showed similar results: 123 (29%) had the marker, and these patients also experienced worse outcomes. The presence of this marker, whether in blood or abdominal fluid, indicated a poorer prognosis.
The study highlights that while surgery is the only known cure, most patients experience cancer spread after surgery. The test helps identify patients less likely to benefit from surgery alone, guiding treatment decisions towards chemotherapy and/or radiation before surgery. For patients without the KRAS mutation (approximately 10% of cases), the test is less conclusive and other tests are needed.
'Historically, we've known that KRAS mutations are associated with a more biologically aggressive pancreatic cancer,' says Jennifer Leiting, M.D., hepatobiliary and pancreatic surgeon within Mayo Clinic's Department of Surgery. Dr. Leiting is first author of the study. 'But this large study gives us a much clearer understanding of how to interpret the test results and use them to improve patient care. It allows for more accurate staging at diagnosis, leading to better treatment decisions.'
The researchers suggest that this test should become a standard part of the initial diagnosis for PDAC, enabling more personalized risk stratification and effective treatment plans.
'This improved diagnostic capability offers hope for patients and their families facing this challenging disease,' says Dr. Truty. 'It's optimistic to see how advances in genetic testing are directly helping our patients.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Mid East Info
5 days ago
- Mid East Info
Mayo Clinic researchers identify a measurable genetic mutation as a significant predictor of metastasis and survival in pancreatic cancer
Dubai, United Arab Emirates; June, 2025 — A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation — KRAS circulating tumor DNA ctDNA— strongly indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma (PDAC). The mutation was identified using a readily available and clinically approved blood and abdominal fluid test. PDAC is an aggressive form of cancer that is often difficult to diagnose. Most patients already have cancer spread to other parts of their body when initially diagnosed, and current tests often miss this hidden spread. This makes it challenging to determine the best treatment strategy. The findings, published in the Annals of Surgical Oncology, may help identify patients who are more likely to have cancer spread to other parts of the body, therefore providing doctors and patients with the right information to make informed decisions about treatment. 'This is a major advancement for pancreatic ductal adenocarcinoma,' says Mark Truty, M.D., hepatobiliary and pancreatic surgical oncologist within Mayo Clinic's Department of Surgery. Dr. Truty is senior author of the study. 'We've had this genetic testing available for a number of years, however, we did not know the significance of the results or how to interpret them. Having the KRAS status will allow the patient and their provider to make better decisions about their individual cancer treatment.' The prospective cohort study, involving nearly 800 patients — the largest patient series to date in the literature using ctDNA — found that 20%-30% of patients with PDAC have detectable mutant KRAS ctDNA in the blood and/or peritoneum, and that those without any previous treatment, such as chemotherapy, had the highest incidence. Thus, the study suggests that ctDNA assays should be performed prior to treatment to have the highest yield. The researchers examined data between 2018 and 2022. Blood sample tests revealed that 104 patients (14%) had KRAS ctDNA mutation. These patients were more likely to develop advanced, spreading cancer and had a lower survival rate. Further testing of fluid from around the abdominal cavity in 419 patients showed similar results: 123 (29%) had the marker, and these patients also experienced worse outcomes. The presence of this marker, whether in blood or abdominal fluid, indicated a poorer prognosis. The study highlights that while surgery is the only known cure, most patients experience cancer spread after surgery. The test helps identify patients less likely to benefit from surgery alone, guiding treatment decisions towards chemotherapy and/or radiation before surgery. For patients without the KRAS mutation (approximately 10% of cases), the test is less conclusive and other tests are needed. 'Historically, we've known that KRAS mutations are associated with a more biologically aggressive pancreatic cancer,' says Jennifer Leiting, M.D., hepatobiliary and pancreatic surgeon within Mayo Clinic's Department of Surgery. Dr. Leiting is first author of the study. 'But this large study gives us a much clearer understanding of how to interpret the test results and use them to improve patient care. It allows for more accurate staging at diagnosis, leading to better treatment decisions.' The researchers suggest that this test should become a standard part of the initial diagnosis for PDAC, enabling more personalized risk stratification and effective treatment plans. 'This improved diagnostic capability offers hope for patients and their families facing this challenging disease,' says Dr. Truty. 'It's optimistic to see how advances in genetic testing are directly helping our patients.'


Mid East Info
26-06-2025
- Mid East Info
Mayo Clinic uncovers brain cell changes that could explain Tourette syndrome - Middle East Business News and Information
Dubai, United Arab Emirates; June , 2025 — A new Mayo Clinic study finds that people with Tourette syndrome have about half as many of a specific type of brain cell that helps calm overactive movement signals as people without the condition. This deficit may be a key reason why their motor signals go unchecked, leading to the involuntary tics that define the disorder. The study, published in Biological Psychiatry, is the first to analyze individual brain cells from people with Tourette disorder. The findings also shed light on how different types of brain cells may interact in ways that contribute to the syndrome's symptoms. 'This research may help lay the foundation for a new generation of treatments,' says Alexej Abyzov, Ph.D., a genomic scientist in Mayo Clinic's Center for Individualized Medicine and a co-author of the study. 'If we can understand how these brain cells are altered and how they interact, we may be able to intervene earlier and more precisely.' Tourette disorder is a neurodevelopmental condition that typically begins in childhood. It causes repeated, involuntary movements and vocalizations such as eye blinking, throat clearing or facial grimacing. While genetic studies have identified some risk genes, the biological mechanisms behind the condition have remained unclear. To better understand what's happening in the brain with Tourette syndrome, Dr. Abyzov and his team analyzed more than 43,000 individual cells from postmortem brain tissue of people with and without the condition. They focused on the basal ganglia, a region of the brain that helps control movement and behavior. In each cell, they looked at how genes were working. They also analyzed how changes in the brain's gene-control systems might trigger stress and inflammation. First, they found in people with Tourette syndrome a 50% reduction in interneurons, which are brain cells that help calm excess signals in the brain's movement circuits. They also observed stress responses in two other brain cell types. Medium spiny neurons, which make up most of the cells in basal ganglia and help send movement signals, showed reduced energy production. Microglia, the brain's immune cells, showed inflammation. The two responses were closely linked, suggesting the cells may be interacting in Tourette disorder. 'We're seeing different types of brain cells reacting to stress and possibly communicating with each other in ways that could be driving symptoms,' says Yifan Wang, Ph.D., co-author of the study. The study also provides evidence that the underlying cause of brain cell changes in Tourette disorder may be linked to parts of DNA that control when genes turn on and off. 'Tourette patients seem to have the same functional genes as everyone else but the coordination between them is broken,' Dr. Abyzov says. Next, the researchers plan to study how these brain changes develop over time and look for genetic factors that may help explain the disorder. The study was conducted in collaboration with the lab of Flora M. Vaccarino, M.D., at Yale University. For a complete list of authors, disclosures and funding, review the study.


Mid East Info
14-06-2025
- Mid East Info
Keolis MHI Drives Social Impact Through Blood Donation Campaign Ahead of World Blood Donor Day - Middle East Business News and Information
Dubai, UAE: In the lead-up to World Blood Donor Day, observed annually on June 14, Keolis MHI, the leading transportation company, proudly partnered with the Dubai Health Authority (DHA) to organize a blood donation drive. This initiative Highlights Keolis MHI's commitment to corporate social responsibility (CSR) and aligns with the UAE's national vision of becoming a global leader in community engagement and sustainable development. The 2025 World Blood Donor Day campaign, 'Give blood, give hope: together we save lives,' highlights the life-saving power of community through blood donation, inspiring new and existing donors with real stories. Keolis MHI's blood donation campaign, held in collaboration with the DHA, reflected the company's values : Imagine, Care, Commit. Employees eagerly participated, demonstrating Keolis MHI's strong belief in how individual actions can significantly boost community well-being. 'At Keolis MHI, we are dedicated to making a positive impact on the communities we serve,' said Adel Al Awadhi, Marketing and Communications Director at Keolis MHI. 'Blood donation is a critical act that can save lives, and we were honored to partner with the DHA to ensure a readily available blood supply for those in need. This drive reflected our core values of community engagement and social responsibility.' The campaign also served as a platform to raise awareness about the urgent need for blood transfusions across a variety of medical scenarios, from emergency surgeries to chronic treatments. By encouraging a culture of voluntary donation, Keolis MHI contributed to building a more resilient and responsive healthcare system for the UAE. More Than a Donation: A Collective Act of Purpose Keolis MHI's involvement went beyond simply organizing an event, it demonstrated a strategic alignment with the UAE's CSR agenda and the national drive to promote public health and sustainable community development. 'Blood donation offers a deeply personal reward, with donors experiencing the satisfaction of potentially saving someone and strengthening their sense of purpose,' Mr. Al Awadhi explained. 'It also reinforces social responsibility and allows individuals to witness the impact of collective action firsthand.' By actively promoting employee participation and promoting the value of giving back, Keolis MHI reinforced its position as a responsible corporate citizen. The initiative not only contributed to public health but also helped build stronger emotional ties within the company and the wider community. Supporting the UAE's Vision for CSR The UAE government has consistently championed CSR principles, encouraging both public and private sectors to integrate social responsibility into the core of their operations. In alignment with this national vision, and with 2025 designated as the Year of Community, Keolis MHI continues to lead by example through impactful initiatives that contribute to the country's economic, social, and environmental development. 'Keolis MHI is committed to being a catalyst for positive change in the UAE,' Mr. Al Awadhi added. 'By actively engaging in initiatives like the blood donation drive, we align ourselves with the UAE's vision of establishing the country as a global leader in corporate social responsibility. Our participation reflects our belief in the power of collective action to create a lasting impact and contribute to the betterment of society.' As we look ahead, we remain committed to engaging in initiatives that support public health, empower our people, and contribute to building a stronger, more compassionate society. At Keolis MHI, we encourage everyone, individuals and organizations alike, to take part in this global movement and experience the true power of giving.